Biocytogen Europe Innovation Center team to Present at AET-EU 2022, introducing Project Integrum, TCR-mimic platform and YH012
Beijing, China and Heidelberg, Germany, June 3, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") today announced 3 poster presentations for two novel fully human antibody platforms and one bispecific ADC asset at Antibody Engineering & Therapeutics Europe (AET-EU) 2022 taking place on June 7-9, 2022 in Amsterdam and online. Antibody BD & licensing team from Biocytogen Europe Innovation Center (BEIC) will be on-site to present posters and booth (#3).
Introducing Biocytogen’s RenMice™ HiTS (Hyperimmune Target Specific) Platform, also called Project Integrum, for identification of new therapeutic antibodies, our BEIC team will present current progress of this platform that features the knocking out of 1000+ potentially druggable targets from fully human antibody RenMice™ (RenMab™ and RenLite®) for the purpose of generating fully human antibodies covering diverse epitopes with high affinity and specificity. Combining with downstream high-throughput in vivo efficacy screening ability, Project Integrum offers a streamlined solution to develop antibodies that recognize novel and challenging targets.
Our team will also present Biocytogen’s novel TCR-mimic platform for discovering fully human antibodies against intracellular targets. The platform utilizes HLA-expressing fully human antibody mice (HLA/RenMab mice) to generate antibodies binding intracellular tumor-associated antigens in the context of HLA when immunized with MHC-antigen-peptide complexes. Subsequently, Biocytogen’s high-throughput antibody screening platform enables a swift identification of TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients. Currently, antibody hits for multiple intracellular targets are undergoing in vitro and in vivo characterization. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.
A preclinical candidate YH012 will also be introduced. It is a HER2 x TROP2 bispecific ADC generated from our proprietary bsADC platform, taking advantages of our common light chain RenLite® mice to acquire bispecific antibodies with high affinity and specificity as well as good stability for downstream drug conjugation. In vivo drug efficacy data shows potent anti-tumor activity.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of first-in-class and/or best-in-class antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit en.biocytogen.com.cn.
For more information, please contact:
Vivian Tian, PhD, MBA
Office: +86 010-56967680
Zimeng Zhang, PhD
Office: +86 010-56967680